menu search

BAYRY / Bayer: Still A Strong Buy Despite Lowered Guidance

Bayer: Still A Strong Buy Despite Lowered Guidance
Bayer reporting disappointing second quarter results with declining sales and lowered the guidance for fiscal 2023. The company is continuing to struggle and total debt increased again and management is now expecting no free cash flow in 2023. But over the long run, Bayer should profit from several headwinds and is operating in three segments with huge addressable markets. Read More
Posted: Aug 22 2023, 00:06
Author Name: Seeking Alpha
Views: 092175

BAYRY News  

Bayer ordered to pay $332 mln in Roundup cancer trial -Law.com

By Reuters
October 31, 2023

Bayer ordered to pay $332 mln in Roundup cancer trial -Law.com

A California jury found Bayer liable in a case brought by a man who claimed his cancer was due to exposure to the company's Roundup weed killer, and o more_horizontal

New Strong Sell Stocks for October 17th

By Zacks Investment Research
October 17, 2023

New Strong Sell Stocks for October 17th

BAYYR, EDAP and FWRD have been added to the Zacks Rank #5 (Strong Sell) List on October 17, 2023. more_horizontal

Gene therapy, Parkinson's disease, and food science: Bayer U.S. discusses the latest technology

By Yahoo Finance
October 15, 2023

Gene therapy, Parkinson's disease, and food science: Bayer U.S. discusses the latest technology

Most Americans know Bayer (BAYN.DE) for its over-the-counter medicines like Aleve and Claritin. But that's not all the company does. more_horizontal

Bayer (BAYRY) Partners Twist Bioscience for Drug Discovery

By Zacks Investment Research
October 6, 2023

Bayer (BAYRY) Partners Twist Bioscience for Drug Discovery

Bayer (BAYRY) collaborates with Twist Bioscience to advance breakthrough innovations based on new scientific approaches and platform technologies. more_horizontal

Key drug in Sudafed, Dayquil and many other decongestants doesn't relieve congestion: FDA

By Market Watch
September 12, 2023

Key drug in Sudafed, Dayquil and many other decongestants doesn't relieve congestion: FDA

WASHINGTON (AP) — The leading decongestant used by millions of Americans looking for relief from a stuffy nose is no better than a dummy pill, accor more_horizontal

Bayer says Parkinson's stem cell therapy improves symptoms in initial trial

By Reuters
August 28, 2023

Bayer says Parkinson's stem cell therapy improves symptoms in initial trial

Bayer said an experimental stem cell therapy developed by its U.S. subsidiary BlueRock had shown signs of easing Parkinson's disease symptoms in an ea more_horizontal

Bayer: Still A Strong Buy Despite Lowered Guidance

By Seeking Alpha
August 22, 2023

Bayer: Still A Strong Buy Despite Lowered Guidance

Bayer reporting disappointing second quarter results with declining sales and lowered the guidance for fiscal 2023. The company is continuing to strug more_horizontal

Bayer Aktiengesellschaft (BAYZF) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 8, 2023

Bayer Aktiengesellschaft (BAYZF) Q2 2023 Earnings Call Transcript

Bayer Aktiengesellschaft (OTCPK:BAYZF) Q2 2023 Earnings Call Transcript August 8, 2023 8:00 AM ET Company Participants Oliver Maier - Head of IR Bill more_horizontal


Search within

Pages Search Results: